Single User License
INR 136340
Site License
INR 272680
Corporate User License
INR 409020

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Diabetic Nephropathy-Pipeline Review, H1 2015

Diabetic Nephropathy-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Diabetic Nephropathy-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Diabetic Nephropathy-Pipeline Review, H1 2015', provides an overview of the Diabetic Nephropathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Diabetic Nephropathy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Diabetic Nephropathy Overview 10

Therapeutics Development 11

Pipeline Products for Diabetic Nephropathy-Overview 11

Pipeline Products for Diabetic Nephropathy-Comparative Analysis 12

Diabetic Nephropathy-Therapeutics under Development by Companies 13

Diabetic Nephropathy-Therapeutics under Investigation by Universities/Institutes 18

Diabetic Nephropathy-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Unknown Stage Products 22

Diabetic Nephropathy-Products under Development by Companies 23

Diabetic Nephropathy-Products under Investigation by Universities/Institutes 27

Diabetic Nephropathy-Companies Involved in Therapeutics Development 28

AbbVie Inc. 28

Aerpio Therapeutics, Inc. 29

Antisense Therapeutics Limited 30

Astellas Pharma Inc. 31

AstraZeneca PLC 32

Bayer AG 33

Bristol-Myers Squibb Company 34

Cellmid Limited 35

ChemoCentryx, Inc. 36

Concert Pharmaceuticals, Inc. 37

CTI BioPharma Corp. 38

Daiichi Sankyo Company, Limited 39

DiaMedica Inc. 40

Dimerix Bioscience Pty Ltd 41

Dong Wha Pharma Co., Ltd. 42

Eli Lilly and Company 43

Galectin Therapeutics, Inc. 44

GenKyoTex S.A. 45

Gentium S.p.A. 46

Gilead Sciences, Inc. 47

GlaxoSmithKline plc 48

Glucox Biotech AB 49

GNI Group Ltd. 50

IMMD Inc. 51

Intercept Pharmaceuticals, Inc. 52

InterMune, Inc. 53

Inventiva SAS 54

Islet Sciences, Inc. 55

Jenrin Discovery, Inc. 56

Johnson & Johnson 57

Mallinckrodt plc 58

Mesoblast Limited 59

Mitsubishi Tanabe Pharma Corporation 60

NephroGenex, Inc. 61

Noxxon Pharma AG 62

Omeros Corporation 63

OncoImmune, Inc. 64

Otsuka Holdings Co., Ltd. 65

Pfizer Inc. 66

PhytoHealth Corporation 67

ProMetic Life Sciences Inc. 68

Serodus ASA 69

Shire Plc 70

Thrasos, Inc. 71

Torrent Pharmaceuticals Limited 72

Vascular Pharmaceuticals, Inc. 73

Diabetic Nephropathy-Therapeutics Assessment 74

Assessment by Monotherapy Products 74

Assessment by Target 75

Assessment by Mechanism of Action 78

Assessment by Route of Administration 81

Assessment by Molecule Type 83

Drug Profiles 85

11-RVIVIT-Drug Profile 85

A-717-Drug Profile 86

APX-115-Drug Profile 87

ASP-7657-Drug Profile 88

ASP-8232-Drug Profile 89

ATL-1103-Drug Profile 90

atrasentan hydrochloride-Drug Profile 92

baricitinib-Drug Profile 94

BMS-813160-Drug Profile 97

canagliflozin-Drug Profile 98

CCX-140-Drug Profile 100

corticotropin-Drug Profile 102

CS-3150-Drug Profile 104

CTP-499-Drug Profile 106

Cyndacel-M-Drug Profile 108

DCB-DN1-Drug Profile 109

DM-199-Drug Profile 110

DMX-250-Drug Profile 112

Drug for Diabetic Nephropathy-Drug Profile 113

Drugs to Activate Nrf2 for Diabetic Cardiomyopathy-Drug Profile 114

DT-23552-Drug Profile 115

DW-1029M-Drug Profile 116

emapticap pegol-Drug Profile 117

finerenone-Drug Profile 119

GKT-136901-Drug Profile 120

GKT-137831-Drug Profile 122

GKT-901-Drug Profile 123

GR-MD-02-Drug Profile 124

GS-4997-Drug Profile 126

GW-610742-Drug Profile 127

hu-91-Drug Profile 129

IMD-1041-Drug Profile 131

INT-767-Drug Profile 132

JD-5037-Drug Profile 134

JNJ-39933673-Drug Profile 135

KBP-5074-Drug Profile 136

lisofylline-Drug Profile 137

Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications-Drug Profile 139

Monoclonal Antibody to Inhibit HPTPbeta for Diabetic Nephropathy-Drug Profile 141

Monoclonal Antibody to Inhibit Midkine for Cancer and Inflammatory Disorders-Drug Profile 142

MSC300-IV-Drug Profile 143

MT-3995-Drug Profile 145

Nephrilin-Drug Profile 146

Oligotide-Drug Profile 147

OX-029-Drug Profile 149

PBI-4050-Drug Profile 150

PF-00489791-Drug Profile 151

PF-04634817-Drug Profile 152

PF-06409577-Drug Profile 153

PHN-033-Drug Profile 154

pirfenidone-Drug Profile 155

pirfenidone-Drug Profile 158

probucol-Drug Profile 160

Pyridoxamine Dihydrochloride-Drug Profile 161

Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders-Drug Profile 163

SER-150-Drug Profile 164

SHP-627-Drug Profile 166

Small Molecule for Diabetic Nephropathy-Drug Profile 167

Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy-Drug Profile 168

Small Molecules for Diabetic Nephropathy-Drug Profile 169

Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders-Drug Profile 170

SP-20202-Drug Profile 172

THRV-123-Drug Profile 173

TRC-120038-Drug Profile 174

VPI-2690-B-Drug Profile 175

Diabetic Nephropathy-Recent Pipeline Updates 177

Diabetic Nephropathy-Dormant Projects 224

Diabetic Nephropathy-Discontinued Products 226

Diabetic Nephropathy-Product Development Milestones 227

Featured News & Press Releases 227

Appendix 234

Methodology 234

Coverage 234

Secondary Research 234

Primary Research 234

Expert Panel Validation 234

Contact Us 234

Disclaimer 235

List of Tables

Number of Products under Development for Diabetic Nephropathy, H1 2015 15

Number of Products under Development for Diabetic Nephropathy-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 18

Number of Products under Development by Companies, H1 2015 (Contd..1) 19

Number of Products under Development by Companies, H1 2015 (Contd..2) 20

Number of Products under Development by Companies, H1 2015 (Contd..3) 21

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Late Stage Development, H1 2015 23

Comparative Analysis by Clinical Stage Development, H1 2015 24

Comparative Analysis by Early Stage Development, H1 2015 25

Comparative Analysis by Unknown Stage Development, H1 2015 26

Products under Development by Companies, H1 2015 27

Products under Development by Companies, H1 2015 (Contd..1) 28

Products under Development by Companies, H1 2015 (Contd..2) 29

Products under Development by Companies, H1 2015 (Contd..3) 30

Products under Investigation by Universities/Institutes, H1 2015 31

Diabetic Nephropathy-Pipeline by AbbVie Inc., H1 2015 32

Diabetic Nephropathy-Pipeline by Aerpio Therapeutics, Inc., H1 2015 33

Diabetic Nephropathy-Pipeline by Antisense Therapeutics Limited, H1 2015 34

Diabetic Nephropathy-Pipeline by Astellas Pharma Inc., H1 2015 35

Diabetic Nephropathy-Pipeline by AstraZeneca PLC, H1 2015 36

Diabetic Nephropathy-Pipeline by Bayer AG, H1 2015 37

Diabetic Nephropathy-Pipeline by Bristol-Myers Squibb Company, H1 2015 38

Diabetic Nephropathy-Pipeline by Cellmid Limited, H1 2015 39

Diabetic Nephropathy-Pipeline by ChemoCentryx, Inc., H1 2015 40

Diabetic Nephropathy-Pipeline by Concert Pharmaceuticals, Inc., H1 2015 41

Diabetic Nephropathy-Pipeline by CTI BioPharma Corp., H1 2015 42

Diabetic Nephropathy-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 43

Diabetic Nephropathy-Pipeline by DiaMedica Inc., H1 2015 44

Diabetic Nephropathy-Pipeline by Dimerix Bioscience Pty Ltd, H1 2015 45

Diabetic Nephropathy-Pipeline by Dong Wha Pharma Co., Ltd., H1 2015 46

Diabetic Nephropathy-Pipeline by Eli Lilly and Company, H1 2015 47

Diabetic Nephropathy-Pipeline by Galectin Therapeutics, Inc., H1 2015 48

Diabetic Nephropathy-Pipeline by GenKyoTex S.A., H1 2015 49

Diabetic Nephropathy-Pipeline by Gentium S.p.A., H1 2015 50

Diabetic Nephropathy-Pipeline by Gilead Sciences, Inc., H1 2015 51

Diabetic Nephropathy-Pipeline by GlaxoSmithKline plc, H1 2015 52

Diabetic Nephropathy-Pipeline by Glucox Biotech AB, H1 2015 53

Diabetic Nephropathy-Pipeline by GNI Group Ltd., H1 2015 54

Diabetic Nephropathy-Pipeline by IMMD Inc., H1 2015 55

Diabetic Nephropathy-Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 56

Diabetic Nephropathy-Pipeline by InterMune, Inc., H1 2015 57

Diabetic Nephropathy-Pipeline by Inventiva SAS, H1 2015 58

Diabetic Nephropathy-Pipeline by Islet Sciences, Inc., H1 2015 59

Diabetic Nephropathy-Pipeline by Jenrin Discovery, Inc., H1 2015 60

Diabetic Nephropathy-Pipeline by Johnson & Johnson, H1 2015 61

Diabetic Nephropathy-Pipeline by Mallinckrodt plc, H1 2015 62

Diabetic Nephropathy-Pipeline by Mesoblast Limited, H1 2015 63

Diabetic Nephropathy-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 64

Diabetic Nephropathy-Pipeline by NephroGenex, Inc., H1 2015 65

Diabetic Nephropathy-Pipeline by Noxxon Pharma AG, H1 2015 66

Diabetic Nephropathy-Pipeline by Omeros Corporation, H1 2015 67

Diabetic Nephropathy-Pipeline by OncoImmune, Inc., H1 2015 68

Diabetic Nephropathy-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 69

Diabetic Nephropathy-Pipeline by Pfizer Inc., H1 2015 70

Diabetic Nephropathy-Pipeline by PhytoHealth Corporation, H1 2015 71

Diabetic Nephropathy-Pipeline by ProMetic Life Sciences Inc., H1 2015 72

Diabetic Nephropathy-Pipeline by Serodus ASA, H1 2015 73

Diabetic Nephropathy-Pipeline by Shire Plc, H1 2015 74

Diabetic Nephropathy-Pipeline by Thrasos, Inc., H1 2015 75

Diabetic Nephropathy-Pipeline by Torrent Pharmaceuticals Limited, H1 2015 76

Diabetic Nephropathy-Pipeline by Vascular Pharmaceuticals, Inc., H1 2015 77

Assessment by Monotherapy Products, H1 2015 78

Number of Products by Stage and Target, H1 2015 80

Number of Products by Stage and Mechanism of Action, H1 2015 83

Number of Products by Stage and Route of Administration, H1 2015 86

Number of Products by Stage and Molecule Type, H1 2015 88

Diabetic Nephropathy Therapeutics-Recent Pipeline Updates, H1 2015 181

Diabetic Nephropathy-Dormant Projects, H1 2015 228

Diabetic Nephropathy-Dormant Projects (Contd..1), H1 2015 229

Diabetic Nephropathy-Discontinued Products, H1 2015 230

List of Figures

Number of Products under Development for Diabetic Nephropathy, H1 2015 15

Number of Products under Development for Diabetic Nephropathy-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 17

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 24

Comparative Analysis by Early Stage Products, H1 2015 25

Assessment by Monotherapy Products, H1 2015 78

Number of Products by Top 10 Targets, H1 2015 79

Number of Products by Stage and Top 10 Targets, H1 2015 79

Number of Products by Top 10 Mechanism of Actions, H1 2015 82

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 82

Number of Products by Top 10 Routes of Administration, H1 2015 85

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 85

Number of Products by Top 10 Molecule Types, H1 2015 87

Number of Products by Stage and Top 10 Molecule Types, H1 2015 87

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Aerpio Therapeutics, Inc.

Antisense Therapeutics Limited

Astellas Pharma Inc.

AstraZeneca PLC

Bayer AG

Bristol-Myers Squibb Company

Cellmid Limited

ChemoCentryx, Inc.

Concert Pharmaceuticals, Inc.

CTI BioPharma Corp.

Daiichi Sankyo Company, Limited

DiaMedica Inc.

Dimerix Bioscience Pty Ltd

Dong Wha Pharma Co., Ltd.

Eli Lilly and Company

Galectin Therapeutics, Inc.

GenKyoTex S.A.

Gentium S.p.A.

Gilead Sciences, Inc.

GlaxoSmithKline plc

Glucox Biotech AB

GNI Group Ltd.

IMMD Inc.

Intercept Pharmaceuticals, Inc.

InterMune, Inc.

Inventiva SAS

Islet Sciences, Inc.

Jenrin Discovery, Inc.

Johnson & Johnson

Mallinckrodt plc

Mesoblast Limited

Mitsubishi Tanabe Pharma Corporation

NephroGenex, Inc.

Noxxon Pharma AG

Omeros Corporation

OncoImmune, Inc.

Otsuka Holdings Co., Ltd.

Pfizer Inc.

PhytoHealth Corporation

ProMetic Life Sciences Inc.

Serodus ASA

Shire Plc

Thrasos, Inc.

Torrent Pharmaceuticals Limited

Vascular Pharmaceuticals, Inc.

Diabetic Nephropathy Therapeutic Products under Development, Key Players in Diabetic Nephropathy Therapeutics, Diabetic Nephropathy Pipeline Overview, Diabetic Nephropathy Pipeline, Diabetic Nephropathy Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com